Search This Blog

Monday, August 29, 2016

New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016





Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.